2014
Low-Frequency NNRTI-Resistant HIV-1 Variants and Relationship to Mutational Load in Antiretroviral-Naïve Subjects
Gupta S, Lataillade M, Kyriakides TC, Chiarella J, St. John EP, Webb S, Moreno EA, Simen BB, Kozal MJ. Low-Frequency NNRTI-Resistant HIV-1 Variants and Relationship to Mutational Load in Antiretroviral-Naïve Subjects. Viruses 2014, 6: 3428-3437. PMID: 25256391, PMCID: PMC4189030, DOI: 10.3390/v6093428.Peer-Reviewed Original ResearchMeSH KeywordsAnti-HIV AgentsDrug Resistance, ViralHIV InfectionsHIV-1HumansMutationMutation RateReverse Transcriptase InhibitorsConceptsNNRTI resistance mutationsMajor NNRTI-resistance mutationsResistance mutationsAntiretroviral-naïve subjectsARV-naïve HIVMajor NNRTI mutationsNNRTI-resistant variantsTreatment-naïve HIVHIV-1 variantsNon-nucleoside reverseMutational loadNaïve HIVNNRTI mutationsNNRTI resistanceVariant frequencyTrue burdenTherapeutic failureTreatment outcomesTreatment responseAa positionsHIVViral variantsFurther evaluationResistant variantsDeep sequencingDeep Sequencing of HIV: Clinical and Research Applications
Chabria SB, Gupta S, Kozal MJ. Deep Sequencing of HIV: Clinical and Research Applications. Annual Review Of Genomics And Human Genetics 2014, 15: 1-31. PMID: 24821496, DOI: 10.1146/annurev-genom-091212-153406.BooksMeSH KeywordsDrug Resistance, ViralGenome, ViralHigh-Throughput Nucleotide SequencingHIVHIV InfectionsHumansMutationConceptsHuman immunodeficiency virusAntiretroviral therapyDrug-resistant human immunodeficiency virusDrug-resistant HIV variantsCare antiretroviral therapyMaximal viral suppressionTreatment-naive individualsDrug resistance mutationsViral quasispeciesViral suppressionDrug selective pressureAntiretroviral agentsSensitive genotyping methodsTreatment failureHIV transmissionImmunodeficiency virusHIV variantsClinical careVaccine developmentViral variantsViral heterogeneityMolecular virologyLow-frequency variantsViral fitnessSequencing-based assays
2009
Raltegravir With Unboosted Atazanavir 300 mg Twice Daily in Antiretroviral Treatment-Experienced Participants
Gupta S, Lataillade M, Farber S, Kozal MJ. Raltegravir With Unboosted Atazanavir 300 mg Twice Daily in Antiretroviral Treatment-Experienced Participants. Journal Of The International Association Of Providers Of AIDS Care (JIAPAC) 2009, 8: 87-92. PMID: 19270153, DOI: 10.1177/1545109709332471.Peer-Reviewed Original ResearchConceptsMean CD4 count increaseCD4 count increaseCombination of raltegravirTreatment-experienced patientsPotent antiretroviral activityCopies/mLProtease inhibitorsARV agentsUnboosted atazanavirHIV RNAImmunologic outcomesTwice DailyAntiretroviral treatmentARV therapyAntiretroviral agentsCase seriesHIV integrase inhibitorsTherapeutic failureAntiretroviral activityRaltegravirAtazanavirIntegrase inhibitorsAdverse effectsCells/Count increase